Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

734 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.
Foeldvari I, Torok KS, Anton J, Blakley M, Constantin T, Curran M, Cutolo M, Denton C, Fligelstone K, Ingegnoli F, Li SC, Němcová D, Orteu C, Pilkington C, Smith V, Stevens A, Klotsche J, Khanna D, Costa-Reis P, Del Galdo F, Hinrichs B, Kasapcopur O, Pain C, Ruperto N, Zheng A, Furst DE. Foeldvari I, et al. Among authors: furst de. Arthritis Care Res (Hoboken). 2023 Dec;75(12):2453-2462. doi: 10.1002/acr.25171. Epub 2023 Sep 12. Arthritis Care Res (Hoboken). 2023. PMID: 37332054 Free article. Review.
Safety of tumour necrosis factor-alpha antagonists.
Khanna D, McMahon M, Furst DE. Khanna D, et al. Among authors: furst de. Drug Saf. 2004;27(5):307-24. doi: 10.2165/00002018-200427050-00003. Drug Saf. 2004. PMID: 15061685 Review.
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group. Khanna D, et al. Among authors: furst de. Arthritis Rheum. 2005 Feb;52(2):592-600. doi: 10.1002/art.20787. Arthritis Rheum. 2005. PMID: 15692967 Free article. Clinical Trial.
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: furst de. J Rheumatol. 2005 May;32(5):832-40. J Rheumatol. 2005. PMID: 15868618 Clinical Trial.
Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage.
Khanna D, Ranganath VK, Fitzgerald J, Park GS, Altman RD, Elashoff D, Gold RH, Sharp JT, Furst DE, Paulus HE; Western Consortium of Practicing Rheumatologists. Khanna D, et al. Among authors: furst de. Arthritis Rheum. 2005 Aug;52(8):2284-92. doi: 10.1002/art.21221. Arthritis Rheum. 2005. PMID: 16052588 Free article.
Scleroderma--developing measures of response.
Furst DE, Khanna D, Mattucci-Cerinic M, Silman AJ, Merkel PA, Foeldvari I; OMERACT 7 Special Interest Group. Furst DE, et al. J Rheumatol. 2005 Dec;32(12):2477-80. J Rheumatol. 2005. PMID: 16331791
Meloxicam in rheumatoid arthritis.
Ahmed M, Khanna D, Furst DE. Ahmed M, et al. Among authors: furst de. Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):739-51. doi: 10.1517/17425255.1.4.739. Expert Opin Drug Metab Toxicol. 2005. PMID: 16863437 Review.
734 results